Abiraterone
The serum concentration of Deutetrabenazine can be increased when it is combined with Abiraterone.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Deutetrabenazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Deutetrabenazine.
Advertisement
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Deutetrabenazine.
Acetyl Sulfisoxazole
The metabolism of Deutetrabenazine can be decreased when combined with Acetyl sulfisoxazole.
Alizapride
The risk or severity of adverse effects can be increased when Alizapride is combined with Deutetrabenazine.
Advertisement
Alprazolam
The risk or severity of sedation and somnolence can be increased when Alprazolam is combined with Deutetrabenazine.
Amiodarone
Amiodarone may increase the QTc-prolonging activities of Deutetrabenazine.
Amisulpride
The risk or severity of adverse effects can be increased when Amisulpride is combined with Deutetrabenazine.
Advertisement
Amobarbital
The risk or severity of sedation and somnolence can be increased when Amobarbital is combined with Deutetrabenazine.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Deutetrabenazine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Deutetrabenazine.
Anagrelide
Anagrelide may increase the QTc-prolonging activities of Deutetrabenazine.
Apalutamide
The serum concentration of Deutetrabenazine can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Deutetrabenazine can be increased when it is combined with Aprepitant.
Aprobarbital
The risk or severity of sedation and somnolence can be increased when Aprobarbital is combined with Deutetrabenazine.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Deutetrabenazine.
Arsenic Trioxide
Arsenic trioxide may increase the QTc-prolonging activities of Deutetrabenazine.
Artemether
The metabolism of Deutetrabenazine can be decreased when combined with Artemether.
Asenapine
The risk or severity of adverse effects can be increased when Asenapine is combined with Deutetrabenazine.
Astemizole
Astemizole may increase the QTc-prolonging activities of Deutetrabenazine.
Atazanavir
The metabolism of Deutetrabenazine can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Deutetrabenazine can be decreased when combined with Atomoxetine.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Deutetrabenazine.
Barbital
The risk or severity of sedation and somnolence can be increased when Barbital is combined with Deutetrabenazine.
Benperidol
The risk or severity of adverse effects can be increased when Benperidol is combined with Deutetrabenazine.
Bepridil
Bepridil may increase the QTc-prolonging activities of Deutetrabenazine.
Betaxolol
The metabolism of Deutetrabenazine can be decreased when combined with Betaxolol.
Boceprevir
The metabolism of Deutetrabenazine can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Deutetrabenazine can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Deutetrabenazine can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Deutetrabenazine can be decreased when it is combined with Bosentan.
Brexpiprazole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Deutetrabenazine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Deutetrabenazine.
Bromopride
The risk or severity of adverse effects can be increased when Bromopride is combined with Deutetrabenazine.
Bromperidol
The risk or severity of adverse effects can be increased when Bromperidol is combined with Deutetrabenazine.
Brotizolam
The risk or severity of sedation and somnolence can be increased when Brotizolam is combined with Deutetrabenazine.
Bupropion
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Deutetrabenazine.
Butabarbital
The risk or severity of sedation and somnolence can be increased when Butabarbital is combined with Deutetrabenazine.
Butalbital
The risk or severity of sedation and somnolence can be increased when Butalbital is combined with Deutetrabenazine.
Butobarbital
The risk or severity of sedation and somnolence can be increased when Butethal is combined with Deutetrabenazine.
Caffeine
The metabolism of Deutetrabenazine can be decreased when combined with Caffeine.
Carbamazepine
The metabolism of Deutetrabenazine can be increased when combined with Carbamazepine.
Cariprazine
The risk or severity of adverse effects can be increased when Cariprazine is combined with Deutetrabenazine.
Celecoxib
The metabolism of Deutetrabenazine can be decreased when combined with Celecoxib.
Ceritinib
The serum concentration of Deutetrabenazine can be increased when it is combined with Ceritinib.
Chloral Hydrate
The risk or severity of sedation and somnolence can be increased when Chloral hydrate is combined with Deutetrabenazine.
Chlordiazepoxide
The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.
Chlormethiazole
The risk or severity of sedation and somnolence can be increased when clomethiazole is combined with Deutetrabenazine.
Chloroquine
Chloroquine may increase the QTc-prolonging activities of Deutetrabenazine.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Deutetrabenazine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Deutetrabenazine.
Cholecalciferol
The metabolism of Deutetrabenazine can be decreased when combined with Cholecalciferol.
Cilostazol
Cilostazol may increase the QTc-prolonging activities of Deutetrabenazine.
Cimetidine
The metabolism of Deutetrabenazine can be decreased when combined with Cimetidine.
Cinacalcet
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Cinacalcet.
Ciprofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Cisapride
Cisapride may increase the QTc-prolonging activities of Deutetrabenazine.
Citalopram
Citalopram may increase the QTc-prolonging activities of Deutetrabenazine.
Clarithromycin
Clarithromycin may increase the QTc-prolonging activities of Deutetrabenazine.
Clemastine
The metabolism of Deutetrabenazine can be decreased when combined with Clemastine.
Clobazam
The metabolism of Deutetrabenazine can be decreased when combined with Clobazam.
Clomipramine
The metabolism of Deutetrabenazine can be decreased when combined with Clomipramine.
Clotrimazole
The metabolism of Deutetrabenazine can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Deutetrabenazine.
Cobicistat
The serum concentration of Deutetrabenazine can be increased when it is combined with Cobicistat.
Cocaine
Cocaine may increase the QTc-prolonging activities of Deutetrabenazine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Deutetrabenazine.
Crizotinib
The metabolism of Deutetrabenazine can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Deutetrabenazine can be decreased when combined with Curcumin.
Cyamemazine
The risk or severity of adverse effects can be increased when Cyamemazine is combined with Deutetrabenazine.
Cyclosporine
The metabolism of Deutetrabenazine can be decreased when combined with Cyclosporine.
Cyproterone Acetate
The serum concentration of Deutetrabenazine can be decreased when it is combined with Cyproterone acetate.
Dabrafenib
The serum concentration of Deutetrabenazine can be decreased when it is combined with Dabrafenib.
Dapiprazole
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Deutetrabenazine.
Darifenacin
The metabolism of Deutetrabenazine can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Deutetrabenazine can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Deutetrabenazine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Deutetrabenazine can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Deutetrabenazine can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Delavirdine.
Desipramine
The metabolism of Deutetrabenazine can be decreased when combined with Desipramine.
Dexmedetomidine
The risk or severity of sedation and somnolence can be increased when Dexmedetomidine is combined with Deutetrabenazine.
Diazepam
The risk or severity of sedation and somnolence can be increased when Diazepam is combined with Deutetrabenazine.
Dichloralphenazone
The risk or severity of sedation and somnolence can be increased when Dichloralphenazone is combined with Deutetrabenazine.
Dihydroergotamine
The metabolism of Deutetrabenazine can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Deutetrabenazine can be decreased when combined with Diltiazem.
Diphenhydramine
The risk or severity of sedation and somnolence can be increased when Diphenhydramine is combined with Deutetrabenazine.
Disopyramide
Disopyramide may increase the QTc-prolonging activities of Deutetrabenazine.
Dofetilide
Dofetilide may increase the QTc-prolonging activities of Deutetrabenazine.
Domperidone
Domperidone may increase the QTc-prolonging activities of Deutetrabenazine.
Donepezil
Donepezil may increase the QTc-prolonging activities of Deutetrabenazine.
Dothiepin
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Dosulepin.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Deutetrabenazine.
Doxycycline
The metabolism of Deutetrabenazine can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Deutetrabenazine can be decreased when combined with Doxycycline.
Dronedarone
Dronedarone may increase the QTc-prolonging activities of Deutetrabenazine.
Droperidol
Droperidol may increase the QTc-prolonging activities of Deutetrabenazine.
Duloxetine
The metabolism of Deutetrabenazine can be decreased when combined with Duloxetine.
Eliglustat
The metabolism of Deutetrabenazine can be decreased when combined with Eliglustat.
Enzalutamide
The serum concentration of Deutetrabenazine can be decreased when it is combined with Enzalutamide.
Erythromycin
Erythromycin may increase the QTc-prolonging activities of Deutetrabenazine.
Escitalopram
Escitalopram may increase the QTc-prolonging activities of Deutetrabenazine.
Estazolam
The risk or severity of sedation and somnolence can be increased when Estazolam is combined with Deutetrabenazine.
Eszopiclone
The risk or severity of sedation and somnolence can be increased when Eszopiclone is combined with Deutetrabenazine.
Ethanol
The risk or severity of sedation and somnolence can be increased when Ethanol is combined with Deutetrabenazine.
Ethchlorvynol
The risk or severity of sedation and somnolence can be increased when Ethchlorvynol is combined with Deutetrabenazine.
Etomidate
The risk or severity of sedation and somnolence can be increased when Etomidate is combined with Deutetrabenazine.
Flecainide
Flecainide may increase the QTc-prolonging activities of Deutetrabenazine.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Deutetrabenazine.
Fluconazole
Fluconazole may increase the QTc-prolonging activities of Deutetrabenazine.
Flunitrazepam
The risk or severity of sedation and somnolence can be increased when Flunitrazepam is combined with Deutetrabenazine.
Fluoxetine
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Deutetrabenazine.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Deutetrabenazine.
Flurazepam
The risk or severity of sedation and somnolence can be increased when Flurazepam is combined with Deutetrabenazine.
Fluspirilene
The risk or severity of adverse effects can be increased when Fluspirilene is combined with Deutetrabenazine.
Fluvoxamine
The metabolism of Deutetrabenazine can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Deutetrabenazine can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Deutetrabenazine can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Deutetrabenazine can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of sedation and somnolence can be increased when Fospropofol is combined with Deutetrabenazine.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Deutetrabenazine.
Fusidate
The serum concentration of Deutetrabenazine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Deutetrabenazine can be increased when it is combined with Fusidic Acid.
Gatifloxacin
Gatifloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Gatifloxacin Anhydrous
Gatifloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Glutethimide
The risk or severity of sedation and somnolence can be increased when Glutethimide is combined with Deutetrabenazine.
Grepafloxacin
Grepafloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Halofantrine
Halofantrine may increase the QTc-prolonging activities of Deutetrabenazine.
Haloperidol
Haloperidol may increase the QTc-prolonging activities of Deutetrabenazine.
Hexobarbital
The risk or severity of sedation and somnolence can be increased when Hexobarbital is combined with Deutetrabenazine.
Hypoxis hemerocallidea root extract
The serum concentration of Deutetrabenazine can be decreased when it is combined with St. John's Wort.
Ibutilide
Ibutilide may increase the QTc-prolonging activities of Deutetrabenazine.
Idelalisib
The metabolism of Deutetrabenazine can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of adverse effects can be increased when Iloperidone is combined with Deutetrabenazine.
Imatinib
The metabolism of Deutetrabenazine can be decreased when combined with Imatinib.
Imipramine
The metabolism of Deutetrabenazine can be decreased when combined with Imipramine.
Indinavir
The metabolism of Deutetrabenazine can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Deutetrabenazine can be decreased when combined with Indinavir.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Deutetrabenazine.
Isavuconazole
The serum concentration of Deutetrabenazine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Deutetrabenazine can be decreased when combined with Isavuconazonium.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Deutetrabenazine.
Isoniazid
The metabolism of Deutetrabenazine can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Deutetrabenazine can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Deutetrabenazine can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Deutetrabenazine can be increased when it is combined with Ivacaftor.
Ketoconazole
The metabolism of Deutetrabenazine can be decreased when combined with Ketoconazole.
Levofloxacin
Levofloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Levofloxacin Anhydrous
Levofloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Levomethadyl
Levomethadyl Acetate may increase the QTc-prolonging activities of Deutetrabenazine.
Lidocaine
The metabolism of Deutetrabenazine can be decreased when combined with Lidocaine.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Deutetrabenazine.
Lithium
The risk or severity of adverse effects can be increased when Lithium is combined with Deutetrabenazine.
Lithium Cation
The risk or severity of adverse effects can be increased when Lithium is combined with Deutetrabenazine.
Lopinavir
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Lopinavir.
Lorazepam
The risk or severity of sedation and somnolence can be increased when Lorazepam is combined with Deutetrabenazine.
Lorcaserin
The metabolism of Deutetrabenazine can be decreased when combined with Lorcaserin.
Lormetazepam
The risk or severity of sedation and somnolence can be increased when Lormetazepam is combined with Deutetrabenazine.
Lovastatin
The metabolism of Deutetrabenazine can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Deutetrabenazine.
Luliconazole
The serum concentration of Deutetrabenazine can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Deutetrabenazine can be increased when combined with Lumacaftor.
Lumefantrine
The metabolism of Deutetrabenazine can be decreased when combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Deutetrabenazine.
Manidipine
The metabolism of Deutetrabenazine can be decreased when combined with Manidipine.
Melatonin
The risk or severity of sedation and somnolence can be increased when Melatonin is combined with Deutetrabenazine.
Mephobarbital
The risk or severity of sedation and somnolence can be increased when Methylphenobarbital is combined with Deutetrabenazine.
Meprobamate
The risk or severity of sedation and somnolence can be increased when Meprobamate is combined with Deutetrabenazine.
Mesoridazine
Mesoridazine may increase the QTc-prolonging activities of Deutetrabenazine.
Methadone
Methadone may increase the QTc-prolonging activities of Deutetrabenazine.
Methapyrilene
The risk or severity of sedation and somnolence can be increased when Methapyrilene is combined with Deutetrabenazine.
Methaqualone
The risk or severity of sedation and somnolence can be increased when Methaqualone is combined with Deutetrabenazine.
Methohexital
The risk or severity of sedation and somnolence can be increased when Methohexital is combined with Deutetrabenazine.
Methotrimeprazine
Methotrimeprazine may increase the QTc-prolonging activities of Deutetrabenazine.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Deutetrabenazine.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Deutetrabenazine.
Methyprylon
The risk or severity of sedation and somnolence can be increased when Methyprylon is combined with Deutetrabenazine.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Deutetrabenazine.
Metoprolol
The metabolism of Deutetrabenazine can be decreased when combined with Metoprolol.
Metylperon
The risk or severity of adverse effects can be increased when Melperone is combined with Deutetrabenazine.
Mexiletine
The metabolism of Deutetrabenazine can be decreased when combined with Mexiletine.
Mianserin
The risk or severity of adverse effects can be increased when Mianserin is combined with Deutetrabenazine.
Midazolam
The risk or severity of sedation and somnolence can be increased when Midazolam is combined with Deutetrabenazine.
Midostaurin
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Midostaurin.
Mifepristone
The serum concentration of Deutetrabenazine can be increased when it is combined with Mifepristone.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Deutetrabenazine.
Mirabegron
The metabolism of Deutetrabenazine can be decreased when combined with Mirabegron.
Mitotane
The serum concentration of Deutetrabenazine can be decreased when it is combined with Mitotane.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Deutetrabenazine.
Molindone
The risk or severity of adverse effects can be increased when Molindone is combined with Deutetrabenazine.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Nefazodone
The metabolism of Deutetrabenazine can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Deutetrabenazine can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Deutetrabenazine can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Deutetrabenazine can be increased when combined with Nevirapine.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Deutetrabenazine.
Nicardipine
The metabolism of Deutetrabenazine can be decreased when combined with Nicardipine.
Nilotinib
The metabolism of Deutetrabenazine can be decreased when combined with Nilotinib.
Nitrazepam
The risk or severity of sedation and somnolence can be increased when Nitrazepam is combined with Deutetrabenazine.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Deutetrabenazine.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Deutetrabenazine.
Olaparib
The metabolism of Deutetrabenazine can be decreased when combined with Olaparib.
Ondansetron
Ondansetron may increase the QTc-prolonging activities of Deutetrabenazine.
Osimertinib
The serum concentration of Deutetrabenazine can be increased when it is combined with Osimertinib.
Oxaliplatin
Oxaliplatin may increase the QTc-prolonging activities of Deutetrabenazine.
Oxazepam
The risk or severity of sedation and somnolence can be increased when Oxazepam is combined with Deutetrabenazine.
Palbociclib
The serum concentration of Deutetrabenazine can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Deutetrabenazine.
Panobinostat
The serum concentration of Deutetrabenazine can be increased when it is combined with Panobinostat.
Papaverine
Papaverine may increase the QTc-prolonging activities of Deutetrabenazine.
Paraldehyde
The risk or severity of sedation and somnolence can be increased when Paraldehyde is combined with Deutetrabenazine.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Deutetrabenazine.
Paroxetine
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Paroxetine.
Peginterferon Alfa-2b
The serum concentration of Deutetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
Pentamidine may increase the QTc-prolonging activities of Deutetrabenazine.
Pentobarbital
The risk or severity of sedation and somnolence can be increased when Pentobarbital is combined with Deutetrabenazine.
Perazine
The risk or severity of adverse effects can be increased when Perazine is combined with Deutetrabenazine.
Periciazine
The risk or severity of adverse effects can be increased when Propericiazine is combined with Deutetrabenazine.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Deutetrabenazine.
Phenobarbital
The risk or severity of sedation and somnolence can be increased when Phenobarbital is combined with Deutetrabenazine.
Phenytoin
The metabolism of Deutetrabenazine can be increased when combined with Phenytoin.
Pimozide
Pimozide may increase the QTc-prolonging activities of Deutetrabenazine.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Deutetrabenazine.
Pipothiazine
The risk or severity of adverse effects can be increased when Pipotiazine is combined with Deutetrabenazine.
Posaconazole
The metabolism of Deutetrabenazine can be decreased when combined with Posaconazole.
Primidone
The risk or severity of sedation and somnolence can be increased when Primidone is combined with Deutetrabenazine.
Probucol
Probucol may increase the QTc-prolonging activities of Deutetrabenazine.
Procainamide
Procainamide may increase the QTc-prolonging activities of Deutetrabenazine.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Deutetrabenazine.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Deutetrabenazine.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deutetrabenazine.
Promazine
The risk or severity of adverse effects can be increased when Promazine is combined with Deutetrabenazine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Deutetrabenazine.
Propiomazine
The risk or severity of adverse effects can be increased when Propiomazine is combined with Deutetrabenazine.
Propofol
Propofol may increase the QTc-prolonging activities of Deutetrabenazine.
Prothipendyl
The risk or severity of adverse effects can be increased when Prothipendyl is combined with Deutetrabenazine.
Quazepam
The risk or severity of sedation and somnolence can be increased when Quazepam is combined with Deutetrabenazine.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Deutetrabenazine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Deutetrabenazine.
Quinidine
Quinidine may increase the QTc-prolonging activities of Deutetrabenazine.
Quinine
The metabolism of Deutetrabenazine can be decreased when combined with Quinine.
Ramelteon
The risk or severity of sedation and somnolence can be increased when Ramelteon is combined with Deutetrabenazine.
Ranolazine
The metabolism of Deutetrabenazine can be decreased when combined with Ranolazine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Deutetrabenazine.
Remifentanil
The risk or severity of sedation and somnolence can be increased when Remifentanil is combined with Deutetrabenazine.
Remoxipride
The risk or severity of adverse effects can be increased when Remoxipride is combined with Deutetrabenazine.
Reserpine
The therapeutic efficacy of Deutetrabenazine can be increased when used in combination with Reserpine.
Rifabutin
The metabolism of Deutetrabenazine can be increased when combined with Rifabutin.
Rifampin
The metabolism of Deutetrabenazine can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Deutetrabenazine can be increased when combined with Rifapentine.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Deutetrabenazine.
Ritonavir
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Ritonavir.
Rolapitant
The metabolism of Deutetrabenazine can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Deutetrabenazine can be decreased when combined with Ropinirole.
Roxithromycin
Roxithromycin may increase the QTc-prolonging activities of Deutetrabenazine.
Rucaparib
The metabolism of Deutetrabenazine can be decreased when combined with Rucaparib.
Saquinavir
The metabolism of Deutetrabenazine can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Deutetrabenazine can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Deutetrabenazine can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.
Scopolamine Hydrobromide
The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.
Secobarbital
The risk or severity of sedation and somnolence can be increased when Secobarbital is combined with Deutetrabenazine.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Deutetrabenazine.
Sertindole
The risk or severity of adverse effects can be increased when Sertindole is combined with Deutetrabenazine.
Sertraline
The metabolism of Deutetrabenazine can be decreased when combined with Sertraline.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Deutetrabenazine.
Sildenafil
The metabolism of Deutetrabenazine can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Deutetrabenazine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Deutetrabenazine can be increased when it is combined with Simeprevir.
Sotalol
Sotalol may increase the QTc-prolonging activities of Deutetrabenazine.
Sparfloxacin
Sparfloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
ST. JOHN'S WORT EXTRACT
The serum concentration of Deutetrabenazine can be decreased when it is combined with St. John's Wort.
Sulfisoxazole
The metabolism of Deutetrabenazine can be decreased when combined with Sulfisoxazole.
Sulpiride
Sulpiride may increase the QTc-prolonging activities of Deutetrabenazine.
Talbutal
The risk or severity of sedation and somnolence can be increased when Talbutal is combined with Deutetrabenazine.
Tasimelteon
The risk or severity of sedation and somnolence can be increased when Tasimelteon is combined with Deutetrabenazine.
Telaprevir
The metabolism of Deutetrabenazine can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Deutetrabenazine can be decreased when combined with Telithromycin.
Temazepam
The risk or severity of sedation and somnolence can be increased when Temazepam is combined with Deutetrabenazine.
Tenofovir Disoproxil
The metabolism of Deutetrabenazine can be decreased when combined with Tenofovir disoproxil.
Terbinafine
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Terbinafine.
Terfenadine
Terfenadine may increase the QTc-prolonging activities of Deutetrabenazine.
Teriflunomide
The serum concentration of Deutetrabenazine can be decreased when it is combined with Teriflunomide.
Terlipressin
Terlipressin may increase the QTc-prolonging activities of Deutetrabenazine.
Tetrabenazine
The therapeutic efficacy of Deutetrabenazine can be increased when used in combination with Tetrabenazine.
Theophylline
The metabolism of Deutetrabenazine can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Deutetrabenazine can be decreased when combined with Theophylline.
Thiamylal
The risk or severity of sedation and somnolence can be increased when Thiamylal is combined with Deutetrabenazine.
Thiethylperazine
The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Deutetrabenazine.
Thiopental
The risk or severity of sedation and somnolence can be increased when Thiopental is combined with Deutetrabenazine.
Thiopental Sodium
The risk or severity of sedation and somnolence can be increased when Thiopental is combined with Deutetrabenazine.
Thioproperazine
The risk or severity of adverse effects can be increased when Thioproperazine is combined with Deutetrabenazine.
Thioridazine
Thioridazine may increase the QTc-prolonging activities of Deutetrabenazine.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Deutetrabenazine.
Tiapride
The risk or severity of adverse effects can be increased when Tiapride is combined with Deutetrabenazine.
Ticlopidine
The metabolism of Deutetrabenazine can be decreased when combined with Ticlopidine.
Tipranavir
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Tipranavir.
Tocilizumab
The serum concentration of Deutetrabenazine can be decreased when it is combined with Tocilizumab.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Deutetrabenazine.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deutetrabenazine.
Triazolam
The risk or severity of sedation and somnolence can be increased when Triazolam is combined with Deutetrabenazine.
Triazulenone
The risk or severity of sedation and somnolence can be increased when Loprazolam is combined with Deutetrabenazine.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Deutetrabenazine.
Triflupromazine
The risk or severity of adverse effects can be increased when Triflupromazine is combined with Deutetrabenazine.
Valerian Root Extract
The risk or severity of sedation and somnolence can be increased when Valerian is combined with Deutetrabenazine.
Vandetanib
Vandetanib may increase the QTc-prolonging activities of Deutetrabenazine.
Vemurafenib
The serum concentration of Deutetrabenazine can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Deutetrabenazine can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Deutetrabenazine can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Deutetrabenazine can be decreased when combined with Voriconazole.
Xylazine
The risk or severity of sedation and somnolence can be increased when Xylazine is combined with Deutetrabenazine.
Yohimbine
The risk or severity of adverse effects can be increased when Yohimbine is combined with Deutetrabenazine.
Zaleplon
The risk or severity of sedation and somnolence can be increased when Zaleplon is combined with Deutetrabenazine.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Deutetrabenazine.
Zolpidem
The risk or severity of sedation and somnolence can be increased when Zolpidem is combined with Deutetrabenazine.
Zopiclone
The risk or severity of sedation and somnolence can be increased when Zopiclone is combined with Deutetrabenazine.
Zotepine
The risk or severity of adverse effects can be increased when Zotepine is combined with Deutetrabenazine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Deutetrabenazine.
